Download Library

Download Library

Document Type
Interim Report for the First Nine Months of 2017
Interim Report for the First Nine Months of 2017
A Phase IIa Study of Tisotumab Vedotin (HuMax®-TF-ADC) in Patients With Relapsed, Recurrent and/or Metastatic Cervical Cancer: Updated Safety and Efficacy – ESGO E-poster – November 2017 (Concin)
A Phase IIa Study of Tisotumab Vedotin (HuMax®-TF-ADC) in Patients With Relapsed, Recurrent and/or Metastatic Cervical Cancer: Updated Safety and Efficacy – ESGO E-poster – November 2017 (Concin)
Subcutaneous Delivery of Daraumumab in Patients with Relapsed or Refractory Multiple Myeloma: PAVO - ASH abstract - November 2017 (Chari)
Subcutaneous Delivery of Daraumumab in Patients with Relapsed or Refractory Multiple Myeloma: PAVO - ASH abstract - November 2017 (Chari)
Safety and Efficacy of Daratumumab Monotherapy in Patients with Heavily Pretreated Relapsed and Refractory Multiple Myeloma: Final Results from GEN501 and SIRIUS - ASH abstract - November 2017 (Usmani)
Safety and Efficacy of Daratumumab Monotherapy in Patients with Heavily Pretreated Relapsed and Refractory Multiple Myeloma: Final Results from GEN501 and SIRIUS - ASH abstract - November 2017 (Usmani)
Daratumumab in Combination with Lenalidomide and Dexamethaone in Patients with Relapsed or Relapsed / Refractory Multiple Myeloma (GEN503): Final Results - ASH abstract - November 2017 (Plesner)
Daratumumab in Combination with Lenalidomide and Dexamethaone in Patients with Relapsed or Relapsed / Refractory Multiple Myeloma (GEN503): Final Results - ASH abstract - November 2017 (Plesner)
Daratumumab, Bortezomib and Dexamethasone vs Bortezomib and Dexamethasone in Relapsed or Refractory Multiple Myeloma: Updated Efficacy and Safety Analysis of CASTOR - ASH abstract - November 2017 (Spencer)
Daratumumab, Bortezomib and Dexamethasone vs Bortezomib and Dexamethasone in Relapsed or Refractory Multiple Myeloma: Updated Efficacy and Safety Analysis of CASTOR - ASH abstract - November 2017 (Spencer)
Daratumumab Monotherapy for Patients with Intermediate or High-risk Smoldering Multiple Myeloma: CENTAURUS - ASH abstract - November 2017 (Hofmeister)
Daratumumab Monotherapy for Patients with Intermediate or High-risk Smoldering Multiple Myeloma: CENTAURUS - ASH abstract - November 2017 (Hofmeister)
Daratumumab in Combination with Pomalidomide and Dexamethasone for Relapsed and/or Refractory Multiple Myeloma in Patients with greater than or equal to 2 Prior Lines of Therapy: Updated Analysis of MMY1001 - ASH abstract - November 2017 (Facon)
Daratumumab in Combination with Pomalidomide and Dexamethasone for Relapsed and/or Refractory Multiple Myeloma in Patients with greater than or equal to 2 Prior Lines of Therapy: Updated Analysis of MMY1001 - ASH abstract - November 2017 (Facon)
Efficacy and Safety of Ofatumumab and Bendamustine Followed by Ofatumumab Maintenance in Patients with Relapsed Indolent Non-Hodgkin's Lymphoma After Prior Rituximab - ASH abstract - November 2017 (Kolibaba)
Efficacy and Safety of Ofatumumab and Bendamustine Followed by Ofatumumab Maintenance in Patients with Relapsed Indolent Non-Hodgkin's Lymphoma After Prior Rituximab - ASH abstract - November 2017 (Kolibaba)
Daratumumab, Lenalidomide and Dexamethasone vs Lenalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma Based on Prior Treatment History, Renal Function, and Cytogenetic Risk: Subgroup Analyses of POLLUX - ASH abstract - November 2017 (Mo
Daratumumab, Lenalidomide and Dexamethasone vs Lenalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma Based on Prior Treatment History, Renal Function, and Cytogenetic Risk: Subgroup Analyses of POLLUX - ASH abstract - November 2017 (Mo
Daratumumab in Combination with Carfilzomib, Lenalidomide and Dexamethasone in Patients with Newly Diagnosed Multiple Myeloma (MMY1001) - ASH abstract - November 2017 (Chari)
Daratumumab in Combination with Carfilzomib, Lenalidomide and Dexamethasone in Patients with Newly Diagnosed Multiple Myeloma (MMY1001) - ASH abstract - November 2017 (Chari)
Phase 3 Randomized Study of Daratumumab Plus Bortezomib, Melphalan, and Prednisone vs Bortezomib, Melphalan, and Prednisone in Newly Diagnosed Multiple Myeloma Patients Ineligible for Transplant (ALCYONE) - ASH abstract - November 2017 (Mateos)
Phase 3 Randomized Study of Daratumumab Plus Bortezomib, Melphalan, and Prednisone vs Bortezomib, Melphalan, and Prednisone in Newly Diagnosed Multiple Myeloma Patients Ineligible for Transplant (ALCYONE) - ASH abstract - November 2017 (Mateos)
Daratumumab in Combination with Carfilzomib and Dexamethasone in Patients with Relapsed Multiple Myeloma (MMY1001) - ASH abstract - November 2017 (Lonial)
Daratumumab in Combination with Carfilzomib and Dexamethasone in Patients with Relapsed Multiple Myeloma (MMY1001) - ASH abstract - November 2017 (Lonial)
Cost-effectiveness of Daratumumab Plus Bortezomib and Dexamethasone Versus Bortezomib Plus Dexamethasone for Treatment of Patients with Multiple Myeloma Who Have Received at Least One Prior Therapy: an Analysis of the CASTOR Trial - ASH abstract - Novembe
Cost-effectiveness of Daratumumab Plus Bortezomib and Dexamethasone Versus Bortezomib Plus Dexamethasone for Treatment of Patients with Multiple Myeloma Who Have Received at Least One Prior Therapy: an Analysis of the CASTOR Trial - ASH abstract - Novembe
Daratumumab, Lenalidomide and Dexamethasone vs Lenalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma: Updated Efficacy & Safety Analysis of POLLUX - ASH abstract - November 2017 (Dimopoulos)
Daratumumab, Lenalidomide and Dexamethasone vs Lenalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma: Updated Efficacy & Safety Analysis of POLLUX - ASH abstract - November 2017 (Dimopoulos)
Results of an Interim Safety Analysis of a Phase II Study of Daratumumab Plus Cyclophosphamide, Bortezomib and Dexamethasone in Previously Untreated and Relapsed Patients with Multiple Myeloma - ASH abstract - November 2017 (Yimer)
Results of an Interim Safety Analysis of a Phase II Study of Daratumumab Plus Cyclophosphamide, Bortezomib and Dexamethasone in Previously Untreated and Relapsed Patients with Multiple Myeloma - ASH abstract - November 2017 (Yimer)
Daratumumab, Bortezomib and Dexamethasone vs Bortezomib and Dexamethasone for Relapsed / Refractory Multiple Myeloma Patients: An Update of Overall Survival in CASTOR - ASH abstract - November 2017 (Lentzsch)
Daratumumab, Bortezomib and Dexamethasone vs Bortezomib and Dexamethasone for Relapsed / Refractory Multiple Myeloma Patients: An Update of Overall Survival in CASTOR - ASH abstract - November 2017 (Lentzsch)
Daratumumab in Combination with Lenalidomide Plus Dexamethasone Results in Persistent Natural Killer Cells with a Distinct Phenotype and Expansion of Effector Memory T-cells in POLLUX - ASH abstract - November 2017 (van de Donk)
Daratumumab in Combination with Lenalidomide Plus Dexamethasone Results in Persistent Natural Killer Cells with a Distinct Phenotype and Expansion of Effector Memory T-cells in POLLUX - ASH abstract - November 2017 (van de Donk)
A Phase IIa Study of Tisotumab Vedotin (HuMax-TF-ADC) in Patients With Relapsed, Recurrent and/or Metastatic Cervical Cancer: Updated Safety and Efficacy - ESGO E-poster - November 2017 (Concin)
A Phase IIa Study of Tisotumab Vedotin (HuMax-TF-ADC) in Patients With Relapsed, Recurrent and/or Metastatic Cervical Cancer: Updated Safety and Efficacy - ESGO E-poster - November 2017 (Concin)
Cost-effectiveness of Daratumumab Plus Lenalidomide Plus Dexamethasone vs Lenalidomide Plus Dexamethasone for Treatment of Patients with Multiple Myeloma Who Have Received at Least One Prior Therapy: an Analysis of the POLLUX Trial - ASH abstract - Novemb
Cost-effectiveness of Daratumumab Plus Lenalidomide Plus Dexamethasone vs Lenalidomide Plus Dexamethasone for Treatment of Patients with Multiple Myeloma Who Have Received at Least One Prior Therapy: an Analysis of the POLLUX Trial - ASH abstract - Novemb
Genmab First Nine Months of 2017 Results Presentation
Genmab First Nine Months of 2017 Results Presentation
A phase I/II safety study of tisotumab vedotin (HuMax-TF-ADC) in patients with solid tumors
A phase I/II safety study of tisotumab vedotin (HuMax-TF-ADC) in patients with solid tumors
A phase IIa study of tisotumab vedotin (HuMax-TF-ADC) in patients with relapsed, recurrent and/or metastatic cervical cancer
A phase IIa study of tisotumab vedotin (HuMax-TF-ADC) in patients with relapsed, recurrent and/or metastatic cervical cancer
A Phase IIA Study of Tisotumab Vedotin (HuMax-TF-ADC) in Patients with Relapsed, Recurrent and / or Metastatic Cervical Cancer - ESMO presentation - September 2017 (Vergote)
A Phase IIA Study of Tisotumab Vedotin (HuMax-TF-ADC) in Patients with Relapsed, Recurrent and / or Metastatic Cervical Cancer - ESMO presentation - September 2017 (Vergote)
A Phase I/II Safety Study of Tisotumab Vedotin (HuMax-TF-ADC) in Patients With Solid Tumours - ESMO Poster - September 2017 (Chenard-Poirier)
A Phase I/II Safety Study of Tisotumab Vedotin (HuMax-TF-ADC) in Patients With Solid Tumours - ESMO Poster - September 2017 (Chenard-Poirier)
Investor Presentation, September 2017
Investor Presentation, September 2017